| Trial ID: | L6627 |
| Source ID: | NCT06191328
|
| Associated Drug: |
Chiglitazar Sodium
|
| Title: |
A Prospective, Open, Self-controlled Study of the Effects of Chiglitazar Sodium on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes Mellitus (T2DM)
|
| Acronym: |
|
| Status: |
NOT_YET_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes
|
| Interventions: |
DRUG: Chiglitazar sodium
|
| Outcome Measures: |
Primary: HbA1c, Change in HbA1c from baseline, 12 weeks of treatment | Secondary: Serum lipid profile, Changes from baseline in sphingomyelin (SMs), ceramide (CER), lysophosphatidylcholine (LPC), phosphatidylethanolamine (PEs), lysophosphatidylethanolamine (LPEs), and phosphatidylcholine (PC), 12 weeks of treatment
|
| Sponsor/Collaborators: |
Sponsor: Yufan Wang
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
40
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2024-01-31
|
| Completion Date: |
2025-12-30
|
| Results First Posted: |
|
| Last Update Posted: |
2024-01-05
|
| Locations: |
Shanghai First People's Hospital, Shanghai, Shanghai, 200080, China
|
| URL: |
https://clinicaltrials.gov/show/NCT06191328
|
